CDK4-dependent phosphorylation of USP35 promotes the growth of ER+ breast cancer through the mTOR-SOX2 axis

The majority of estrogen receptor-positive (ER + ) breast cancers are treated with endocrine therapy plus CDK4/6 or mTOR inhibitors, but resistance persists. Deubiquitinase USP35 overexpression promotes tumor growth, yet its regulation by post-translational modifications remains unknown. We showed that CDK4 phosphorylated USP35 at Ser982, which was critical for ER+ breast cancer cell growth in vitro and in vivo. Mechanistically, USP35 interacted with TSC2, Ser982 contributed to USP35-mediated reduction of TSC2 protein and its association with TSC1, thereby activating mTOR signaling. Elevated signaling upregulated SOX2, driving oncogenic effects. Importantly, the CDK4/6 or mTOR inhibitor effectively suppressed the growth of USP35-high ER+ breast cancer cells and tumors. Furthermore, the phospho-USP35 Ser982 was positively correlated with the phospho-4E-BP1 level in ER+ breast cancer tissues. Our findings uncover that CDK4/USP35/mTOR/SOX2 signaling axis promotes ER+ breast cancer progression. ER+ breast cancer with high phospho-USP35 S982 level might benefit from CDK4/6 or mTOR inhibitor-based therapies.

Authors

Institutions

Publication Details

Journal
Communications Biology
Published
2026-11-21
DOI
https://doi.org/10.1038/s42003-026-11337-y
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CDK4-dependent phosphorylation of USP35 promotes the growth of ER+ breast cancer through the mTOR-SOX2 axis

Haihua Gu, Rixu Lin, Jiawei Cao, 陈佳园 et al.
Communications Biology
PI3K/AKT/mTOR signaling in cancer
article

CDK4-dependent phosphorylation of USP35 promotes the growth of ER+ breast cancer through the mTOR-SOX2 axis

Haihua Gu, Rixu Lin, Jiawei Cao, 陈佳园, Shuifeng Liang, Ju Huang, Jiayi Shao, Dejin Shi, Guang Wu, Jiayu Chen, Tao Wu, Licai He, Junfeng Lai
article en

Abstract

The majority of estrogen receptor-positive (ER + ) breast cancers are treated with endocrine therapy plus CDK4/6 or mTOR inhibitors, but resistance persists. Deubiquitinase USP35 overexpression promotes tumor growth, yet its regulation by post-translational modifications remains unknown. We showed that CDK4 phosphorylated USP35 at Ser982, which was critical for ER+ breast cancer cell growth in vitro and in vivo. Mechanistically, USP35 interacted with TSC2, Ser982 contributed to USP35-mediated reduction of TSC2 protein and its association with TSC1, thereby activating mTOR signaling. Elevated signaling upregulated SOX2, driving oncogenic effects. Importantly, the CDK4/6 or mTOR inhibitor effectively suppressed the growth of USP35-high ER+ breast cancer cells and tumors. Furthermore, the phospho-USP35 Ser982 was positively correlated with the phospho-4E-BP1 level in ER+ breast cancer tissues. Our findings uncover that CDK4/USP35/mTOR/SOX2 signaling axis promotes ER+ breast cancer progression. ER+ breast cancer with high phospho-USP35 S982 level might benefit from CDK4/6 or mTOR inhibitor-based therapies.

Communications Biology
Wenzhou Medical University (CN), First Affiliated Hospital of Wenzhou Medical University (CN)
PI3K/AKT/mTOR signaling in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon